Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares

Posted by George Bondi on Aug 20th, 2026

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) EVP Christopher Hite sold 100,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $59.97, for a total transaction of $5,997,000.00. Following the completion of the transaction, the executive vice president directly owned 370,401 shares of the company’s stock, valued at $22,212,947.97. This trade represents a 21.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Hite also recently made the following trade(s):

On Tuesday, June 30th, Christopher Hite sold 100,000 shares of Royalty Pharma stock. The stock was sold at an average price of $56.52, for a total transaction of $5,652,000.00.
On Tuesday, June 30th, Christopher Hite sold 30,000 shares of Royalty Pharma stock. The shares were sold at an average price of $56.46, for a total value of $1,693,800.00.
On Tuesday, June 23rd, Christopher Hite sold 150,000 shares of Royalty Pharma stock. The shares were sold at an average price of $54.40, for a total value of $8,160,000.00.

Royalty Pharma Trading Up 3.4%

Shares of RPRX opened at $61.73 on Thursday. Royalty Pharma PLC has a 1 year low of $34.08 and a 1 year high of $61.80. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 0.88. The stock has a 50 day simple moving average of $57.13 and a 200-day simple moving average of $51.61. The stock has a market cap of $35.49 billion, a PE ratio of 42.57, a PEG ratio of 1.39 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. On average, sell-side analysts predict that Royalty Pharma PLC will post 5.3 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.5%. Royalty Pharma’s dividend payout ratio (DPR) is presently 64.83%.

Institutional Investors Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Barton Investment Management acquired a new position in Royalty Pharma during the 1st quarter valued at about $905,000. Nomura Asset Management Co. Ltd. grew its position in shares of Royalty Pharma by 16.2% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 172,418 shares of the biopharmaceutical company’s stock worth $6,662,000 after buying an additional 24,048 shares during the period. Qsemble Capital Management LP acquired a new stake in shares of Royalty Pharma during the 4th quarter worth approximately $2,875,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Royalty Pharma during the fourth quarter worth approximately $4,923,000. Finally, Thrivent Financial for Lutherans raised its stake in shares of Royalty Pharma by 10.4% during the fourth quarter. Thrivent Financial for Lutherans now owns 233,320 shares of the biopharmaceutical company’s stock worth $9,016,000 after buying an additional 22,015 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

RPRX has been the topic of several analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $66.00 target price on shares of Royalty Pharma in a report on Thursday, August 6th. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Morgan Stanley reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, TD Cowen raised their price objective on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $60.86.

View Our Latest Research Report on RPRX

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.